Entity
Description
  • Value proposition

    Accelerating global drug development

    Cytochroma predict how drugs will react in a global population in health or disease.
    Our unique, ethnically diverse library of iPSC and automated cell culture generates robust, reliable, mature hepatocytes for toxicity testing.
    We are supporting life science companies, de-risking safe compounds prior to clinical testing, making new drug development faster, safer and more efficient.

    toxicity testing, liver specialists, hepatocyte testing, disease models, high throughput, high content screening, iPSC, automated manufacture, machine learning, artificial intelligence, predictive testing, and pre clinical testing

  • Advanced human iPSC cell models

    Cytochroma manufacture iPSC derived hepatocytes, cardiomyocytes, endothelial cells and fibroblasts for preclinical testing. Polarised, metabolic and highly functional Cytochrome P450 expressing hepatocytes. Complex, self organising cardiomyocyte models from isogenic fibroblasts and endothelial cells. Genetically diverse models, DILI testing and phenotypic screening. Tiny organs big impact

  • https://cytochroma.org/
Corporate interactions
Corporate TypeTweets Articles
AstraZeneca
AstraZeneca
Pharmaceutical, Pharmaceutical Manufacturing
AstraZeneca
Pharmaceutical, Pharmaceutical Manufacturing
Other

30 Jun 2022


UK Atomic Energy Authority
UK Atomic Energy Authority
Research, National and local authorities
UK Atomic Energy Authority
Research, National and local authorities
Other

31 Dec 2021


Similar entities
Loading...
Loading...
Social network dynamics